Rep. David Taylor (R-OH) Buys Amgen Inc. Shares
House member David Taylor purchases Amgen shares valued between $1,001 and $15,000.
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. David Taylor (R-OH)
- Status:
- Member — House
- State/District:
- OH-2
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 15, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Amgen Inc. ($AMGN) | Buy | Jun 5, 2026 | $1,001 - $15,000 |
Key Points
- David Taylor, a member of the House, bought Amgen shares valued between $1,001 and $15,000 on June 5, 2026.
- Amgen stock trades near $355.2 with a market cap of $191.7 billion and a forward P/E of 15.13.
- Analysts have set new price targets for Amgen, with Piper Sandler maintaining a 'buy' rating and a $427 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Taylor, a member of the U.S. House of Representatives, recently purchased shares of Amgen Inc. (NASDAQ: AMGN). The transaction, reported on June 15, 2026, involved buying shares valued between $1,001 and $15,000. This move adds a political figure to the list of investors in the healthcare giant.
David Taylor vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Amgen
Amgen has seen varying levels of interest from institutional investors. BlackRock, Inc. slightly trimmed its holdings by 295,666 shares, ending with 47,100,472 shares valued at about $16.57 billion. Vanguard Capital Management LLC made a significant addition, acquiring 35,014,232 shares, now holding the same amount worth approximately $12.32 billion. State Street Corp reduced its stake by 42,915 shares, leaving it with 30,548,488 shares valued at $10.75 billion. Meanwhile, Capital World Investors increased its position by 6,190,632 shares, totaling 29,288,343 shares worth about $10.30 billion.
Amgen Inc. Stock Down 17.0%
Shares of Amgen Inc. trade near $355.2. The company has a market capitalization of approximately $191.7 billion. It sports a P/E ratio of 24.68 and a forward P/E of 15.13, indicating expectations of future earnings growth. Amgen's stock has a 52-week low of $267.83 and a high of $391.29. The 50-day moving average is $340.31, while the 200-day moving average is $330.73. The company's beta is 0.416, suggesting lower volatility compared to the broader market.
Recent Earnings
Amgen reported a revenue of $37.22 billion, with a growth rate of 5.8%. The company's earnings per share (EPS) stand at $14.39, and it has a net margin of 20.96%. Return on equity (ROE) is a robust 101.32%. The next earnings report is expected on August 4, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Amgen offers an annual dividend rate of $10.08, yielding 2.84%. The dividend payout ratio is 67.22%, indicating a healthy distribution of profits back to shareholders.
Insider Buying and Selling at Amgen Inc.
Several insiders purchased shares on May 19, 2026. Charles Holley, Ellen Jamison Kullman, Greg Garland, Wanda Austin, Brian Druker, and Tyler Jacks each bought 665 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 10, 2026, Morgan Stanley maintained a 'hold' rating with a $340 price target. Piper Sandler, on May 14, 2026, reaffirmed a 'buy' rating with a target of $427. The consensus rating for Amgen is a 'buy', with a mean target price of $352.5 from 30 analysts.
About Amgen
Amgen Inc., headquartered in Thousand Oaks, California, is a leading biotechnology company in the healthcare sector. It specializes in discovering, developing, manufacturing, and delivering human therapeutics. The company is known for products like Enbrel, Otezla, and Prolia, which treat a range of conditions from arthritis to osteoporosis. With over 31,500 employees, Amgen operates globally and partners with other major firms to expand its product offerings.
Bottom Line
David Taylor's purchase of Amgen shares highlights ongoing interest in this major biotechnology firm. With substantial institutional activity and analyst attention, Amgen remains a significant player in the healthcare market. Remember, the disclosed trades reflect past actions and may not indicate current holdings.
Get Amgen Inc. alerts
New 13F filings, insider trades, and analyst moves on $AMGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.